A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 202 participants.
Also called NCT05036135
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 202 participants
- Sponsor
- Aerovate Therapeutics
- Registry
-
NCT05036135
-
- Other papers using this trial's data
- Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Israel, Italy, Latvia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05036135. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-02 (actual); primary completion 2024-08-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
- Acronym
- IMPAHCT
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- AV-101
- Intervention (Drug)
- Placebo
- Lead sponsor
- Aerovate Therapeutics
Record details
- Record id
cardio:ct-nct05036135- Content hash
59b0cb483390bdd3c91531ccdefac888ddb19ab41e593b9188dc62b8774cccb3